Informed by nature
and guided by science
Informed
by nature
and guided
by science
Our key focus area is palliative care. In particular, Psyence is targeting the indications of anxiety and depression, and associated ailments, within the context of palliative care.
Bringing together leaders in the business of medicine and science
Our scientific and medical team are experts in neurology and the development and commercialisation of pharmaceutical products. Our global executive team has extensive capital market and business building experience and a track record for creating shareholder value and achieving sustainable growth.
Our News
Psyence Group Inc. Announces RSU Grants
Psyence Group Inc. (CSE: PSYG) ("Psyence" or the "Company"), announces that it granted an aggregate of 721,448 restricted share units (each an "RSU") to certain executives, officers, directors and consultants of the Company pursuant to the Company’s Amended and Restated Restricted Share Unit Plan, of which one third vests six months after the grant date, another one third after twelve months and the remaining balance after eighteen months.
Psyence Group INC. Enters Into A Letter Of Intent To Acquire Goldcoast Resource Corp.
Psyence Group Inc. (CSE: PSYG) ("Psyence" or the "Company"), announces that it has entered into a letter of intent (the "LOI") to acquire all of the issued and outstanding securities and securities convertible into securities of GoldCoast Resource Corp. (the "Target" or "GoldCoast"), a corporation existing under the laws of Ontario (the "Acquisition").The Acquisition constitutes a "Change of Business" under the Canadian Securities Exchange ("CSE") policies.
Psyence Group Inc. Closes Second Tranche of Non-Brokered Private Placement for Remaining Proceeds
TORONTO, ONTARIO, July 7, 2025 – Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”), is pleased to announce that it has successfully closed the second tranche (“Tranche 2”) of its previously announced non‑brokered private placement (the “Offering”), relying on the accredited investor exemption under section 2.3 of National Instrument 45-106 — Prospectus Exemptions.
